Replies to post #249912 on Biotech Values

[DewDiligence]

EYPT seeking $201M* in public offering:

https://www.globenewswire.com/news-release/2023/12/04/2790454/0/en/EyePoint-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock.html

EYPT is striking while the iron is hot. However, I question the clinical utility of a drug-eluting implant for AMD that requires a “bailout” injection of anti-VEGF therapy during the first six months in more than one-third of the treated eyes.

*Assuming exercise of underwriter’s option.